High-yield points
- Closed loop: RNS detects and treats, and its recordings help refine localization. Benefit builds over years .
- Children: about 75% median reduction and about 10% seizure-free in pooled data. Lesional and directly targeted cases do better .
- Neocortical: put strips or depth leads at the onset zone. Closer is better early . Eloquent and motor cortex can be treated safely .
- Mesial temporal: depth leads. Bilateral foci are fine, and outcome doesn't depend on exact hippocampal position .
- Thalamic (CM): for multifocal or generalized epilepsy. About 60% respond, with sensorimotor side effects that bipolar or low-frequency stimulation can fix .
- Young children: check skull thickness on CT, fit the device to the skull contour, and consider a larger craniectomy for growth. Watch for infection .
Landmark papers
- Pivotal RNS trial (Morrell et al., Neurology 2011): randomized sham-controlled trial in 191 adults. Seizures fell 37.9% with responsive stimulation vs 17.3% with sham, with no mood or cognitive worsening .
Responsive neurostimulation (RNS) is a closed-loop system. A cranially mounted neurostimulator records electrocorticography from 2 leads, detects seizure patterns and delivers brief stimulation. It is FDA-approved for adults with 1 or 2 seizure foci and is used off-label in children . There are two broad strategies:
- Neocortical or mesial temporal: leads on or in the seizure onset zone, for unresectable or eloquent foci.
- Thalamic: depth leads in a thalamic nucleus, most often the centromedian (CM), for multifocal or generalized epilepsy.
Adult evidence that underpins pediatric use
- Pivotal randomized trial (191 adults): seizures fell 37.9% with responsive stimulation vs 17.3% with sham during the blinded period, with no difference in adverse events and no mood or cognitive worsening .
- Long-term (230 adults, 9 years):
- Median seizure reduction was 75%, and 73% were responders.
- 18.4% had at least 1 year of seizure freedom.
- No serious stimulation-related adverse events occurred .
- Real-world post-approval study (324 adults): median reduction was 82% at 3 years, with similar results for 1 or 2 foci and for mesial temporal, neocortical or combined onsets .
- Benefit grows over time, so judge results over years rather than months .
Evidence in children
- Pooled individual-patient data (98 children, median age 14):
- Median seizure reduction was 75% at a median of 12 months, and 9.7% became seizure-free.
- Complications occurred in 8.4%, half of them device infections.
- MRI-negative cases did worse, and direct targeting was associated with stronger response .
- Meta-analysis plus case series (105 children): RNS reduced seizures across focal, multifocal and generalized epilepsies. Prior VNS and an epilepsy syndrome made near-complete remission less likely .
- Multicenter pediatric series (35 patients, 17 younger than 18, youngest 3 years):
- 41% had at least 50% fewer seizures, and 6% became seizure-free.
- No complications occurred in children. Outcomes didn't differ from young adults or the adult literature .
- Safety series: infection is the main complication. In one series, 3 of 27 children had infections, and 2 needed partial or full device removal; there were no hemorrhages or strokes .
Neocortical and mesial temporal targeting
- Place leads on or in the seizure onset zone, usually defined by SEEG or subdural mapping.
- Strips cover neocortical surface foci.
- Depth leads reach mesial temporal or deep neocortical foci .
- Neocortical onset (126 adults):
- Median reduction was 70% for frontal and parietal onsets, 58% for temporal neocortical and 51% for multilobar.
- Lesional cases did better (77% vs 45% with normal MRI).
- Stimulation caused no neurological deficits, even in eloquent cortex .
- Primary motor cortex (20 patients): 79% were responders and 53% had at least 90% reduction, with no stimulation side effects .
- Mesial temporal onset (111 adults, 72% bilateral):
- Median reduction was 70%.
- Most had depth leads only (76), some depth plus strip (29), and a few strips only (6).
- Outcome did not depend on depth-lead position relative to the hippocampus .
- SEEG-guided neocortical depth leads (55 patients, 87 leads):
- Median reduction rose from 66.7% at 1 year to 77.5% later, and 18.2% became seizure-free.
- At 1 year, closer proximity of the lead to the SEEG-defined focus predicted better outcomes in strong responders .
- In children: RNS works in focal cortical dysplasia and can be combined with resection. Two-device (two-canister) systems have been used for broad or multifocal networks .
Thalamic targeting (RNS)
- Rationale: for multifocal or generalized epilepsy without a single resectable focus .
- CM is the usual thalamic target:
- Pediatric-onset epilepsy (16 patients, ages 3.6–22; 6 younger than 12): 62% were responders. 50% had sensorimotor side effects, and 19% had pocket infections needing device removal .
- Idiopathic generalized or rapidly generalizing epilepsy (21 patients): mean reduction was 82.6%, with a median of about 7 months to worthwhile benefit. Targeting accuracy improved after the first cases .
- LGS case report (2 children): 75–99% seizure reduction .
- Pooled thalamic RNS data: median reduction was 73% (median age 17) .
- Pediatric single centers:
- In thalamic RNS (11 CM, 2 ANT), 46% were responders. Focal cortical dysplasia and bilateral thalamocortical configurations did best .
- In a cohort comparing thalamic DBS and RNS (26 children), responder rates were 83.3% with DBS vs 50% with RNS .
- Combinations: a thalamic lead can be paired with a cortical lead (thalamocortical RNS) . Bilateral pulvinar RNS has been used for posteriorly dominant multifocal epilepsy (see Deep Brain Stimulation for Epilepsy in Children).
How CM-RNS leads are placed and programmed (pediatric series)
- Planning: CM was outlined on gadolinium-enhanced T1 MPRAGE MRI by a neuroradiologist, adapting to each child's anatomy and head size. Trajectories avoided vessels, and leads were placed with a Leksell frame. CT confirmed position .
- Starting settings: 160 µs pulse width, 125 Hz, 0.5 µC/cm² charge density, titrated up to 0.5–2 µC/cm² .
- Side effects: paresthesias, painful shocks, dystonic posturing and nystagmus occurred mainly with monopolar-cathodal stimulation. They were relieved by switching to bipolar, slower titration or low-frequency stimulation .
- For CM targeting anatomy and sweet spots, see Deep Brain Stimulation for Epilepsy in Children.
Device placement in young children
- The skull matters:
- The neurostimulator sits in a craniectomy. Skulls grow fast in the first 2 years and reach about 90% of adult volume by age 7 .
- Assess skull thickness on preoperative CT. A 3-year-old was implanted at a site where the skull was 4 mm thick .
- Fit the curve:
- Contour the device to the skull, usually parietal, to reduce skin breakdown where the scalp is thin .
- A slightly larger craniectomy can accommodate growth .
- Infection is the commonest complication in children: 8.4% complications pooled (half infections), and 19% pocket infections in one CM series .
Related topics
- DBS for Epilepsy: the open-loop thalamic alternative.
- Intracranial EEG: defining the seizure onset zone.
- Temporal Lobe Epilepsy Surgery: mesial temporal targets.
- Lennox–Gastaut Syndrome: thalamic neuromodulation.
- Epilepsy Surgery Overview: surgical context.
- Responsive Neurostimulation (RNS) Placement: step-by-step procedure.
References
- Morrell MJ; RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011;77(13):1295–1304. doi:10.1212/WNL.0b013e3182302056. PMID 21917777. verified
- Panov F, Ganaha S, Haskell J, et al. Safety of responsive neurostimulation in pediatric patients with medically refractory epilepsy. J Neurosurg Pediatr 2020;26(5):525–532. doi:10.3171/2020.5.PEDS20118. PMID 33861559. verified
- Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology 2020;95(9):e1244–e1256. doi:10.1212/WNL.0000000000010154. PMID 32690786. verified
- Eliashiv D, Rao VR, Jobst BC, et al. Postapproval study for brain-responsive neurostimulation for drug-resistant focal epilepsy: three-year efficacy and interim safety results. Neurology 2026;106(9):e214875. doi:10.1212/WNL.0000000000214875. PMID 42030518. verified
- Levy AS, Bystrom LL, Brown EC, et al. Responsive neurostimulation for treatment of pediatric refractory epilepsy: a pooled analysis of the literature. Clin Neurol Neurosurg 2023;234:108012. doi:10.1016/j.clineuro.2023.108012. PMID 37839147. verified
- Rosenberg A, Wang R, Petchpradub M, et al. Responsive neurostimulation in pediatric epilepsy: a systematic review and individual patient meta-analysis supplemented by a single institution case series in 105 aggregated patients. Childs Nerv Syst 2024;40(11):3709–3720. doi:10.1007/s00381-024-06546-x. PMID 39060746. verified
- Nagahama Y, Zervos TM, Murata KK, et al. Real-world preliminary experience with responsive neurostimulation in pediatric epilepsy: a multicenter retrospective observational study. Neurosurgery 2021;89(6):997–1004. doi:10.1093/neuros/nyab343. PMID 34528103. Full text (PMC) verified
- Jobst BC, Kapur R, Barkley GL, et al. Brain-responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas. Epilepsia 2017;58(6):1005–1014. doi:10.1111/epi.13739. PMID 28387951. verified
- Geller EB, Skarpaas TL, Gross RE, et al. Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy. Epilepsia 2017;58(6):994–1004. doi:10.1111/epi.13740. PMID 28398014. verified
- Sadeghzadeh S, Purger DA, Bhanot P, et al. sEEG-guided responsive neurostimulation to treat neocortical epilepsy: a multicenter retrospective study of the efficacy and safety of depth electrode-mediated neuromodulation. Epilepsia Open 2026;11(1):146–161. doi:10.1002/epi4.70180. PMID 41251192. Full text (PMC) verified
- Jung BC, Ho V, Quraishi I, et al. Responsive neurostimulation targeting the primary motor cortex for treatment of drug-resistant epilepsy. Seizure 2026;137:27–31. doi:10.1016/j.seizure.2026.02.024. PMID 41780246. verified
- Enner S, El-Hallal M, Hogan K, et al. Safety & feasibility of responsive neurostimulation in children with refractory epilepsy: a single-center experience. Seizure 2024;114:121–124. doi:10.1016/j.seizure.2023.12.005. PMID 38141494. verified
- Mohanty D, Houck KM, Trandafir C, et al. Responsive neurostimulation of thalamic nuclei for regional and multifocal drug-resistant epilepsy in children and young adults. J Neurosurg Pediatr 2024;34(1):40–48. doi:10.3171/2024.2.PEDS23531. PMID 38608307. verified
- Bystrom LL, Levy AS, Brown EC, et al. Thalamic responsive neurostimulation for the treatment of refractory epilepsy: an individual patient data meta-analysis. J Neurosurg Pediatr 2023;32(3):366–375. doi:10.3171/2023.5.PEDS22559. PMID 37347644. verified
- Ahn S, Edmonds B, Rajaraman RR, et al. Bilateral centromedian nucleus of thalamus responsive neurostimulation for pediatric-onset drug-resistant epilepsy. Epilepsia 2024;65(8):e131–e140. doi:10.1111/epi.18031. PMID 38845459. Full text (PMC) verified
- Nanda P, Sisterson N, Walton A, et al. Centromedian region thalamic responsive neurostimulation mitigates idiopathic generalized and multifocal epilepsy with focal to bilateral tonic-clonic seizures. Epilepsia 2024;65(9):2626–2640. doi:10.1111/epi.18070. PMID 39052021. verified
- Kwon CS, Schupper AJ, Fields MC, et al. Centromedian thalamic responsive neurostimulation for Lennox-Gastaut epilepsy and autism. Ann Clin Transl Neurol 2020;7(10):2035–2040. doi:10.1002/acn3.51173. PMID 32860345. verified
- Nistal D, Edmonds B, Barrios-Anderson A, et al. Thalamic neuromodulation for pediatric drug-resistant epilepsy: a case series evaluating deep brain stimulation and responsive neurostimulation. J Neurosurg Pediatr 2026;38(4):456–464. doi:10.3171/2026.3.PEDS25489. PMID 42537226. verified
Verification (2026-11-02): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. The pediatric skull-growth, skull-thickness and device-placement points come from the full text of reference 7, and the CM-RNS planning and programming details from the full text of reference 15, both on PMC. References 1, 3, 4, 8–11, 14 and 16 are adult or mixed-age. The statements that strips cover surface foci and depth leads reach deep foci, and that leads are placed at the SEEG-defined onset zone, are standard practice summarized from references 8–10. Two-canister (two-device) placement is from reference 12. The schematic is an original figure.